This article summarized the latest R&D progress of cysteamine hydrochloride, the Mechanism of Action for cysteamine hydrochloride, and the drug target R&D trends for cysteamine hydrochloride.

Eli Lilly along with POINT Biopharma Global, Inc. have declared a final agreement where Lilly will take over POINT, a company specializing in radiopharmaceuticals.

TTF, in comparison to PFS, synthesizes the effectiveness and safety characteristics of the drug, encompasses treatment failure for any reason and includes death.

This article summarized the latest R&D progress of cyclizine hydrochloride, the Mechanism of Action for cyclizine hydrochloride, and the drug target R&D trends for cyclizine hydrochloride.

Event-Free Survival (EFS), compared to Disease-Free Survival (DFS), adds a surgical intervention criterion and is often used to evaluate neoadjuvant therapy pre-surgery, or radiotherapy.

Alvotech along with Kashiv Biosciences LLC have publicized their exclusive licensing accord for AVT23 (also called ADL018).

Disease Control Rate refers to the proportion of patients who, according to internationally recognized criteria for alleviating evaluation, achieve tumor relief (PR+CR) and stable disease (SD) after treatment and can maintain for the minimum duration requirement.

This article summarized the latest R&D progress of choline alfoscerate, the Mechanism of Action for choline alfoscerate, and the drug target R&D trends for choline alfoscerate.

PFS is a tumor measurement-based endpoint that primarily evaluates the anti-tumor activity of a drug and, to a certain extent, considers the drug's safety and patient survival (accidental death).

ALX Oncology Holdings Inc. announced encouraging initial results from Phase 2 of its ASPEN-06 trial. The trial evaluates the use of its CD47 blocker, evorpacept, with trastuzumab, CYRAMZA®, and paclitaxel in treating HER2-positive gastric/gastroesophageal junction cancer patients.

ORR is an index directly measuring the anti-tumor activity of a drug and is the most common endpoint based on tumor measurements, evaluated in single-arm trials.

This article summarized the latest R&D progress of cefroxadine, the Mechanism of Action for cefroxadine, and the drug target R&D trends for cefroxadine.